Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Down 93.4% in January

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 8,100 shares, a decrease of 93.4% from the January 15th total of 123,100 shares. Based on an average daily volume of 371,000 shares, the days-to-cover ratio is presently 0.0 days.

Chugai Pharmaceutical Trading Down 0.3 %

CHGCY traded down $0.06 during midday trading on Friday, reaching $23.68. The company's stock had a trading volume of 136,874 shares, compared to its average volume of 179,294. The firm has a market capitalization of $77.93 billion, a price-to-earnings ratio of 28.91 and a beta of 0.81. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $26.00. The stock's 50-day moving average is $21.82 and its 200-day moving average is $22.67.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 22.16%. As a group, equities research analysts forecast that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.